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Introduction
============

Tumor necrosis factor (TNF) inhibitors are utilized for the treatment of a variety of autoimmune diseases, but have also been associated with the paradoxical emergence of autoimmune phenomena, including cutaneous vasculitis. There have also been several reported cases of systemic vasculitis following treatment with Adalimumab without mention of specific patient details or circumstances \[[@REF1]\]. Anti-neutrophilic cytoplasmic antibody (ANCA) vasculitis has been rarely described.

Case presentation
=================

We present the case of a 57-year-old male with past medical history significant for coronary artery disease, hypertension and granuloma annulare (GA) who was admitted with rapid decline in renal function and shortness of breath. GA was being treated with adalimumab for the last two years. Eight months prior to admission, he was noted to have an asymptomatic elevation in his blood urea nitrogen and creatinine (Table [1](#TAB1){ref-type="table"}) which worsened five months later. Renal ultrasound was performed which showed bilateral echogenic kidneys. He was lost to follow up and represented to his primary care provider three months later with a one-week history of epistaxis, hemoptysis, anorexia and weight loss. He was asked to report to the emergency room.

###### Laboratory data on admission

ANA: Anti-Nuclear Antibody; p-ANCA: perinuclear Anti-Neutrophilic Cytoplasmic Antibody; AI: Antibody Index; c-ANCA: cytoplasmic Anti-Neutrophilic Cytoplasmic Antibody.

  ---------------------------------------- ------------------------ -------------------- --------------------
  Laboratory Test                          Results                                        
                                           During hospitalization   Three months prior   Eight months prior
  Blood urea nitrogen (7-18 mg/dl)         136                      51                   32
  Creatinine (0.55-1.3 mg/dl)              15.89                    3.4                  2.6
  Hemoglobin (13.5-18 gm/dl)               6.1                                            
  ANA Titre (Negative)                     1:80 (homogenous)                              
  p-ANCA Titre (\<1:20)                    1:40                                           
  Proteinase 3 antibody (\<1 AI)           \<1                                            
  Myeloperoxidase antibody (\<1AI)         5                                              
  c-ANCA (Negative)                        Negative                                       
  C3 complement (82-185 mg/dl)             130                                            
  C4 complement (15-35 mg/dl)              34                                             
  Hepatitis B surface antigen (Negative)   Negative                                       
  Hepatitis C virus antibody (Negative)    Negative                                       
  ---------------------------------------- ------------------------ -------------------- --------------------

CT chest showed bilateral pulmonary consolidation and ground glass opacities (Figures [1](#FIG1){ref-type="fig"}, [2](#FIG2){ref-type="fig"}). Renal biopsy performed revealed pauci-immune, rapidly progressive glomerulonephritis with some fibrosis (Figure [3](#FIG3){ref-type="fig"}). ANCA with perinuclear staining and myeloperoxidase antibody were positive. He was started on hemodialysis immediately. He also received intravenous methylprednisolone 500 mg daily for three days followed by oral prednisone 60 mg daily, oral cyclophosphamide 125 mg daily (which was eventually transitioned to intravenous monthly pulses of cyclophosphamide) and trimethoprim-sulfamethoxazole for pneumocystis prophylaxis. Adalimumab was discontinued.
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Two months after his hospitalization, pulmonary infiltrates have resolved, but there has been no recovery of renal function.

Discussion
==========

To our knowledge, there have only been nine previously reported cases of vasculitis and positive ANCA that were thought to be induced by TNF inhibitors \[[@REF2]-[@REF9]\]. See Table [2](#TAB2){ref-type="table"} for clinical presentation and treatment of each patient. One patient had atypical ANCA and lupus nephritis (Patient 8) and one patient had aortitis (Patient 9) which are not consistent with true ANCA-associated vasculitis. Of the remaining seven patients, four patients were females and six were being treated for rheumatoid arthritis. The mean age for patients was 51.4 years. Time of onset of symptoms after starting a TNF inhibitor varied from three months to four years. Four of these patients had positive c-ANCA, three had a positive p-ANCA. Six of seven patients had renal biopsies showing pauci-immune glomerulonephritis. Six patients were treated with intravenous methylprednisolone followed by oral prednisone. The TNF inhibitor was discontinued in all cases except patient 7. The most commonly used immunosuppressant was cyclophosphamide in six of seven patients. Four patients had persistent renal dysfunction and one patient died within nine months of presentation. Given the temporal sequence of events, a causal relationship might be present. One proposed mechanism is that anti-TNF drugs form immune complexes, activate complement and promote switching from a T-helper type 1 response (mediated by interleukin (IL)-1, TNF and interferon (IFN)-Y) to a T-helper type 2 response (IL-4, IL-5, IL-6, IL-10 and IL-13) leading to the production of autoantibodies \[[@REF10]\].

###### Vasculitis with positive ANCA induced by TNF- inhibitors

ANCA: Anti-Neutrophilic Cytoplasmic Antibody; TNF-i: Tumor Necrosis Factor inhibitor; CD: Crohn's Disease; GN: Glomerulonephritis; Hb: Hemoglobin; CRP: C-Reactive Protein; RBC: Red Blood Cell; PR-3: Proteinase-3; IV: Intravenous; MP: Methylprednisolone; RA: Rheumatoid Arthritis; UPC: Urine Protein Creatinine; ANA: Anti-Nuclear Antibody; dsDNA: double stranded Deoxyribonucleic Acid; anti-GBM: anti-Glomerular Basement Membrane; HCQ: Hydroxychloroquine; MTX: Methotrexate; HD: Hemodialysis; ESR: Erythrocyte Sedimentation Rate; RF: Rheumatoid factor; MPO: Myeloperoxidase; SS: Sjogren's Syndrome; CrCl: Creatinine Clearance; PO: Per Oral; TMP: Trimethoprim; AZA: Azathioprine; RTX: Rituximab; Cr: Creatinine.

  ------------- --------- ------------ ---------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------------- -----------------------------------------------------------
  Patient No.   Age/Sex   TNF-i        Indication for TNF-i   Time of onset  after starting TNF-i (months)   Clinical presentation                                                                                                                                                   Labs                                                                                                                                                     ANCA type       Other serologies                                                                                         Pathology                                                                                                    Previous/Concomitant drugs                                  Treatment                                                                          Outcome
                54/M      Adalimumab   CD                     30                                             Fever, asthenia, lower extremity edema, inflammatory arthritis, polyneuropathy and optic neuritis, anemia, GN                                                           Hb: 9 gm/dl, CRP: 7.9 mg/dl, Urine studies: 1.2 gm protein/day \>50 RBCs/hpf Granular casts                                                              C-ANCA PR3      \-                                                                                                       Pauci-immune extracapillary GN (Kidney)                                                                      \-                                                          IV MP, IV CYC                                                                      Persistent renal dysfunction C-ANCA negative
                62/F      Adalimumab   RA                     48                                             Malaise, weight loss nasal stuffiness, visual blurring, rash, GN                                                                                                        Urine studies: 3+ blood 3+ protein UPC 5.9 g                                                                                                             C-ANCA PR3      (+) ANA1:640 (-) dsDNA (-) anti-GBM (-) anti- Cardiolipin, Normal complements                            Pauci-immune mild segmental sclerosis with no tubuloreticular lesions (Kidney)                               HCQ, Sulfasalazine, MTX                                     IVMP, Plasma exchange, 1 HD PO prednisone, CYC                                     Improved UPC Persistent renal dysfunction Improved C-ANCA
                67/F      Etanercept   RA                     3                                              Painful, erythematous ulcerated nodules, nasal congestion, peripheral neuropathy, polyarthritis, scleritis, GN pulmonary parenchymal nodules, chronic sinusitis on CT   Hb 13 gm/dl, ESR 111 mm/hr, CRP 15.3 mg/dl, Urine Studies: Hematuria                                                                                     C-ANCA          (+) RF (45 IU/ml) (+) ANA 1:320 homogenous                                                               Leukocytoclastic (Skin)                                                                                      MTX, Prednisolone                                           IVMP pulses, CYC 750/month Steroid taper                                           Good clinical response
                33/F      Infliximab   RA                     16                                             Synovitis anemia GN                                                                                                                                                     Hb 8.8 gm/dl, Cr 0.6 mg/dl (CrCl 82.5 ml/min), ESR 56 mm/hr, CRP 2.5 mg/dl, Urine Studies: 3+ protein 3+ occult blood, 24 hr urine protein: 1.2 gm/day   MPO PR3         (-) Anti-DNA (-) Anti-GBM   Normal IgG, IgA, IgM Normal complement                                       IgM deposition (weak intensity) IgG, IgA, C3, C1q and kappa and Lambda chains (-)- Necrotizing GN (Kidney)   MTX, Sulfasalazine, Bucillamine, Cyclosporine               IVMP, PO prednisone                                                                Good clinical response
                31/M      Infliximab   RA                     8                                              Synovitis rash GN                                                                                                                                                       Cr 3.4 mg/dl (CrCl 54 ml/min), CRP 9.1 mg/dl, Urine Studies: 3+ blood 24 hr Urine protein 1.5 gm                                                         C-ANCA PR3      (+) ANA 1:320 (homogenous) (-) dsDNA (+) RF (-) HepB and C serology (-) Cryoglobulin Normal complement   Pauci-immune crescentic GN (Kidney), Non diagnostic (Skin)                                                   MTX, Cyclosporine Sulfasalazine, HCQ leflunomide            TMP, 1 gm IVMP for 3 days, Oral CYC 2 mg/kg daily. AZA                             Good clinical response Decreased PR3
                58/F      Adalimumab   RA                     48                                             Asymptomatic rapidly progressive GN Alveolar hemorrhage with pulmonary biopsy showing pauci-immune vasculitis anemia                                                    Hb 6.2 gm/dl, CRP \< 10 mg/dl, Urine Studies: RBCs+, 2.47 gm spot urine protein                                                                          P-ANCA MPO      (-) GBM (-) dsDNA (+) RF (+) ANA 1:640 homogeneous (+) SS-A & SS-B                                       Pauci-immune necrotizing GN-extracapillary necrotizing GN (Kidney)                                           D-penicillamine, Gold, MTX, steroids                        IVMP, PO prednisone, Plasma exchanges-7 over 2 weeks, IV CYC six courses HD, AZA   Persistent renal dysfunction
                55/M      Etanercept   RA                     4                                              Alopecia maculopapular rash lower extremity sensory neuropathy GN                                                                                                       Cr. 3 mg/dl, Urine Studies: 1+ protein \>5 RBCs/hpf 5 WBCs/hpf no casts 24 hr urinary protein - 1 gm/day                                                 P-ANCA          (+) ANA 1:320 (-) anti-dsDNA Normal C3 and C4                                                            Pauci-immune focal, segmental, necrotizing and crescentic GN (Kidney)                                        MTX                                                         IV CYC                                                                             Died
                52/F      Adalimumab   RA                     3                                              Gross hematuria and acute renal failure, GN                                                                                                                             Urine Studies: 3+ protein \>20 RBC/hpf granular casts 3.8 gm proteinuria                                                                                 Atypical ANCA   (+) RF (+) ANA 1:640 homogenous, (+) dsDNA 1:25 IgG (-) cryoglobulin Decreased C3 and C4                 Focal proliferative lupus nephritis (class 3) (Kidney)                                                       Prednisone, MMF, Infliximab, MTX, HCQ Penicillamine, Gold   Pulse IVMP PO steroids for 1 month                                                 Persistent renal dysfunction
                65/F      Etanercept   AS                     36                                             Worsening cervical pain Severe and extensive aortitis on CTA chest and abdomen                                                                                          Hb 9 mg/dl, ESR \> 100 mm/hr, CRP 23.9 mg/dl                                                                                                             C-ANCA MPO      Borderline ANA (-) RF Normal complements                                                                                                                                                                                                                                          IVMP 1 g for 3 days, RTX, Prednisone                                               Good clinical response
  ------------- --------- ------------ ---------------------- ---------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------- ---------------------------------------------------------------------------------- -----------------------------------------------------------

Conclusions
===========

TNF-induced ANCA vasculitis is exceedingly rare. These cases in conjunction with ours suggest a possible relationship between anti-TNF use and induction of ANCA vasculitis. To the best of our knowledge, our case is the 4th to describe TNF-induced pulmonary renal syndrome as a manifestation of ANCA-vasculitis. It is difficult to conclusively prove that it is not just a spontaneous emergence of ANCA in a patient predisposed to autoimmunity. However, the biological plausibility of shifting towards a T-helper 2 type response in a susceptible individual leading to the emergence of these antibodies among others, remains. Additionally, this subset of patients appears to have a predilection for rapidly progressive kidney injury with long-term impairment despite discontinuation of the anti-TNF agent. This highlights the need for further studies looking into recognizing risk factors for the development of this rare but significant complication.
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